Clorox (CLX) Price Target Increased to $146.00 by Analysts at Wells Fargo & Co

Clorox (NYSE:CLX) had its target price boosted by analysts at Wells Fargo & Co from $130.00 to $146.00 in a note issued to investors on Thursday, January 4th. The firm currently has a “market perform” rating on the stock. Wells Fargo & Co’s target price would suggest a potential upside of 3.58% from the stock’s previous close.

A number of other brokerages also recently commented on CLX. Zacks Investment Research downgraded shares of Clorox from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Jefferies Group reissued a “hold” rating and issued a $132.00 price target (down from $137.00) on shares of Clorox in a research note on Friday, October 6th. Morgan Stanley reduced their price target on shares of Clorox from $138.00 to $128.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 2nd. Consumer Edge raised shares of Clorox from a “neutral” rating to an “outperform” rating in a research note on Friday, November 10th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $150.00 price target on shares of Clorox in a research note on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $134.33.

Clorox (NYSE CLX) opened at $140.96 on Thursday. The company has a debt-to-equity ratio of 3.02, a quick ratio of 0.77 and a current ratio of 1.10. Clorox has a 52 week low of $118.41 and a 52 week high of $150.40. The company has a market cap of $18,307.99, a PE ratio of 25.58, a price-to-earnings-growth ratio of 3.71 and a beta of 0.42.

Clorox (NYSE:CLX) last issued its earnings results on Wednesday, November 1st. The company reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.05. Clorox had a net margin of 11.84% and a return on equity of 161.59%. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.48 billion. During the same period in the previous year, the firm earned $1.36 earnings per share. Clorox’s quarterly revenue was up 4.0% compared to the same quarter last year. equities analysts predict that Clorox will post 5.7 EPS for the current fiscal year.

In related news, SVP Matthew T. Laszlo sold 20,051 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total transaction of $2,615,853.46. Following the sale, the senior vice president now directly owns 10,896 shares of the company’s stock, valued at approximately $1,421,492.16. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael R. Costello sold 10,574 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the sale, the senior vice president now directly owns 34,867 shares in the company, valued at $4,742,260.67. The disclosure for this sale can be found here. 1.00% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Sun Life Financial INC increased its stake in Clorox by 10,344.4% during the 2nd quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after buying an additional 931 shares during the period. Acrospire Investment Management LLC acquired a new position in Clorox during the 2nd quarter worth approximately $133,000. Salem Investment Counselors Inc. grew its holdings in Clorox by 2.5% during the 2nd quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after acquiring an additional 31 shares in the last quarter. Phocas Financial Corp. acquired a new position in Clorox during the 2nd quarter worth approximately $167,000. Finally, Jacobi Capital Management LLC grew its holdings in Clorox by 0.3% during the 2nd quarter. Jacobi Capital Management LLC now owns 1,286 shares of the company’s stock worth $172,000 after acquiring an additional 4 shares in the last quarter. 73.14% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Clorox (CLX) Price Target Increased to $146.00 by Analysts at Wells Fargo & Co” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/13/clorox-clx-pt-raised-to-146-00.html.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply